Adoptive cell therapy for hard - to - treat blood cancers, after all, are widely expected to be the standard of care within a decade, and it should therefore grow to become one of the most lucrative markets in all of biotech. (fool.com)
In addition to checkpoint blockade antibodies, the editors also pointed to recent advances in adoptive cell therapy — removing a patient's immune cells, engineering them in the lab, and then re-infusing them back into the patient to fight cancer. (cancerresearch.org)
We are investigating this T cell response in newly generated CD1c transgenic mice, and developing an «off - the - shelf» adoptive cell therapy strategy with T cells engineered with CD1c - restricted, leukemia - specific TCRs, which can be applied to all patients with CD1c + leukemia recurrence following bone marrow transplantation. (research.hsr.it)